Clinical trials: Oxaliplatin, open to volunteers
Gastric Adenocarcinoma
Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT07867392
- Testing
- Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1）
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy and Safety of Intraoperative Radiotherapy Combined With Serplulimab Plus Chemotherapy Versus Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
This study evaluates the clinical efficacy and safety benefits of neoadjuvant intraoperative radiotherapy combined with immunotherapy and chemotherapy by comparing intraoperative radiotherapy plus serplulimab plus chemotherapy…
- Trial name
- NICT-IORT (NCT07870798)
- Testing
- Serplulimab, Intraoperative exploration plus intraoperative radiotherapy, Intraoperative exploration without intraoperative radiotherapy
- Volunteers
- 68 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread…
- Trial name
- NCT07775287
- Testing
- Petosemtamab, Cetuximab, Bevacizumab
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- Genmab
Malignant Neoplam, Advanced Solid Tumors
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids.
- Trial name
- NCT07793942
- Testing
- MK-2010, Pembrolizumab, 5-Fluorouracil
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal…
- Conditions
- Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04615013
- Testing
- Capecitabine, Carboplatin, Docetaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral…
- Trial name
- KANDLELIT-001 (NCT05067283)
- Testing
- Calderasib, Pembrolizumab, carboplatin
- Where
- 75 sites in United States, Argentina and 19 more
- Volunteers
- 830 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment…
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Trial name
- NCT06469944
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine
- Where
- 50 sites in United States, Brazil and 10 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Adenocarcinoma, Rectal Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
- Trial name
- NCT06997497
- Testing
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium
- Where
- 244 sites in United States, Argentina and 27 more
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer (CRC)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the…
- Trial name
- HARMONi-GI3 (NCT07228832)
- Testing
- Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
- Where
- 236 sites in United States, Belgium and 13 more
- Volunteers
- 600 people
- Sponsor
- Summit Therapeutics
Rectal Cancer, Radiotherapy
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
This is a prospective, single-arm, biomarker-stratified, multicenter phase 2 clinical trial. All enrolled patients first receive short-course radiotherapy (SCRT), followed by measurement of serum β-hydroxybutyrate (β-HB) levels…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
- Trial name
- NCT07847229
- Testing
- Short-course radiotherapy, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Tao Zhang
Advanced Solid Tumors, Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination…
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
- Trial name
- NCT06840886
- Testing
- PHST001, Paclitaxel, Topotecan
- Where
- 20 sites in United States
- Volunteers
- 426 people
- Sponsor
- Pheast Therapeutics
Gastroesophageal Adenocarcinoma
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
This study will test a new personalized treatment approach for patients with stomach or esophageal cancer. It will take place in two stages and aims to find the best combination of chemotherapy, immunotherapy, and targeted drugs…
- Trial name
- AACR-ADOPT-GEA (NCT07290985)
- Testing
- Tislelizumab, Leucovorin, Oxaliplatin
- Where
- 4 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- American Association for Cancer Research
Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
- Conditions
- Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
- Trial name
- NCT07678593
- Testing
- GFH276, Cetuximab, Nab paclitaxel
- Where
- 17 sites in Australia, China
- Volunteers
- 222 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Borderline Resectable Pancreatic Ductal Adenocarcinoma
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer
This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment response for patients with pancreatic cancer that may be able to be…
- Trial name
- NCT07705919
- Testing
- Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma
Perioperative chemotherapy with the FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is a standard treatment for resectable gastric and gastroesophageal junction adenocarcinoma.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
- Trial name
- NCT07859254
- Testing
- FLOT Chemotherapy
- Where
- Colombia
- Volunteers
- 90 people
- Sponsor
- Fundación Santa Fe de Bogota
Gastroesophageal Junction Adenocarcinoma
Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer
This is a multicenter, prospective, single-arm, open-label exploratory clinical study evaluating sintilimab combined with neoadjuvant chemotherapy, concurrent chemoradiotherapy, and optional consolidation chemotherapy in patients…
- Trial name
- NCT07859410
- Testing
- Sintilimab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Anhui Medical University
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology